Navigation Links
Saladax Biomedical, Inc. to Present at the Annual UBS Global Life Sciences Conference in New York City
Date:9/13/2011

BETHLEHEM, Pa., Sept. 13, 2011 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Edward L. Erickson, president and CEO of Saladax, will be presenting at the Annual UBS Global Life Sciences Conference at the Grand Hyatt New York in New York City on Tuesday, September 20, 2011 at 12:30 p.m. EDT. The company will also be available for one-on-one meetings during the day.  The management presentation will include an overview of the company's business strategy, commercialization progress, products, strategic alliances and development pipeline.

The UBS Global Life Sciences Conference is among the largest healthcare investor conferences in the world.  Senior executives from the leading pharmaceutical, biotechnology and medical technology companies will provide their insight and outlook on the global life sciences industry.

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics.  The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life.  The Company's 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology.  The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU).  This assay is sold by Saladax in Europe as a CE-marked product and will be distributed in Japan by FALCO biosystems.  In the United States and Canada, Myriad Genetic Laboratories, Inc. provides testing for 5-FU dose optimization under the trademark OnDose® through a license to Saladax proprietary technology.  Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds.  For more information, visit www.saladax.com, or follow us on Twitter at https://twitter.com/Saladax.

Saladax Biomedical, Inc.
Edward L. Erickson
President and Chief Executive Officer
eerickson@saladax.com

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
amielach@tiberend.com
or
Jason Rando
jrando@tiberend.com


'/>"/>
SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Companys Board of Directors
2. Saladax Biomedical, Inc. Announces European Commercialization Team
3. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
4. ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells
5. Balan Biomedical, Inc. Announces the Formation of Battery Consulting Group
6. Metabolic Solutions Development Company Presents New Brown Fat Research at the European Association for the Study of Diabetes
7. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
8. Palatin Technologies, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference
9. HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP Congress
10. Americord Registry Presents Abstract on Stem Cell Collection Method at 2011 COSTEM Conference and AABB Meeting
11. Debiopharm Group™ Presents the Debiopharm Group™ Life Sciences Award 2011 and two Junior Debiopharm Group™ Awards 2011 at the ISREC 2011 Life Sciences Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ACEA Biosciences, Inc. announced today that it will ... AC0010 at the World Conference on Lung Cancer 2016, taking place in Vienna, Austria ... I/II clinical trials for AC0010 in patients with advanced non-small cell lung cancer harboring ...
(Date:12/2/2016)... ... December 01, 2016 , ... Aerocom Healthcare ( ... hospitals, will present its chain-of-custody solution for tracking and securing medications at booth ... Dec. 4-8, 2016. , Aerocom has a proven solution for tracking medications via ...
(Date:12/2/2016)... ... 2016 , ... The Conference Forum has announced that the 3rd annual ... on February 1-3, 2017 at the Roosevelt Hotel in New York City. Led by ... unique 360-degree approach, which addresses the most up-to-date information regarding business aspects, clinical advancements ...
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, ... on their recent FDA Class II 510(k) clearance for their flagship medical device, ... commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. While other companies ...
Breaking Biology Technology:
(Date:11/16/2016)... CLARA, Calif. , Nov. 16, 2016 ... enhancing user experience and security for consumer electronics, ... for the financial and retail industry, today announced ... secure and convenient way to authenticate users of ... uses Sensory,s TrulySecure™ software which requires ...
(Date:11/15/2016)... -- Research and Markets has announced the addition of ... to their offering. ... The global bioinformatics ... USD 6.21 Billion in 2016, growing at a CAGR of 21.1% ... market is driven by the growing demand for nucleic acid and ...
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
Breaking Biology News(10 mins):